Suppression of KSHV-induced angiopoietin-2 inhibits angiogenesis, infiltration of inflammatory cells, and tumor growth

References

• Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-69; PMID:7997879; http://dx.doi.org/10.1126/science.7997879
   PubMed Web of Science ®Google Scholar
• Boshoff C, Weiss RA. Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus. Philos Transa R Soc Lond B Biol Sci 2001; 356:517-34; http://dx.doi.org/10.1098/rstb.2000.0778
   PubMed Web of Science ®Google Scholar
• Boshoff C. Kaposi's sarcoma biology. IUBMB Life 2002; 53:259-61; PMID:12121006; http://dx.doi.org/10.1080/15216540212645
   PubMed Web of Science ®Google Scholar
• Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004; 36:687-93; PMID:15220918; http://dx.doi.org/10.1038/ng1384
   PubMed Web of Science ®Google Scholar
• Wang L, Wakisaka N, Tomlinson CC, DeWire SM, Krall S, Pagano JS, Damania B. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 2004; 64:2774-81; PMID:15087393; http://dx.doi.org/10.1158/0008-5472.CAN-03-3653
   PubMed Web of Science ®Google Scholar
• Hensler HR, Rappocciolo G, Rinaldo CR, Jenkins FJ. Cytokine production by human herpesvirus 8-infected dendritic cells. J Gen Virol 2009; 90:79-83; PMID:19088276; http://dx.doi.org/10.1099/vir.0.006239-0
   PubMed Web of Science ®Google Scholar
• Murakami-Mori K, Mori S, Bonavida B. Molecular pathogenesis of AIDS-associated Kaposi's sarcoma: growth and apoptosis. Adv Cancer Res 2000; 78:159-97; PMID:10547670; http://dx.doi.org/10.1016/S0065-230X(08)61025-8
   PubMed Web of Science ®Google Scholar
• Sivakumar R, Sharma-Walia N, Raghu H, Veettil MV, Sadagopan S, Bottero V, Varga L, Levine R, Chandran B. Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications. J Virol 2008; 82:1759-76; PMID:18057235; http://dx.doi.org/10.1128/JVI.00873-07
   PubMed Web of Science ®Google Scholar
• Xu Y, Ganem D. Induction of chemokine production by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Gen Viol 2007; 88:46-50; http://dx.doi.org/10.1099/vir.0.82375-0
   PubMed Web of Science ®Google Scholar
• Bala K, Bosco R, Gramolelli S, Haas DA, Kati S, Pietrek M, Havemeier A, Yakushko Y, Singh VV, Dittrich-Breihdz O, et al. Kaposi's sarcoma herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLCgamma1 and activating NFAT1-dependent RCAN1 expression. PLoS Pathog 2012; 8:e1002927.
   Google Scholar
• Klouche M, Carruba G, Castagnetta L, Rose-John S. Virokines in the pathogenesis of cancer: focus on human herpesvirus 8. Ann N Y Acad Sci 2004; 1028:329-39; PMID:15650258
   PubMed Web of Science ®Google Scholar
• Lindahl P, Hellstrom M, Kalen M, Betsholtz C. Endothelial-perivascular cell signaling in vascular development: lessons from knockout mice. Curr Opin Lipidol 1998; 9:407-11; PMID:9812194; http://dx.doi.org/10.1097/00041433-199810000-00004
   PubMed Web of Science ®Google Scholar
• Patan S. TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res 1998; 56:1-21; PMID:9683559; http://dx.doi.org/10.1006/mvre.1998.2081
   PubMed Web of Science ®Google Scholar
• Sato TN, Qin Y, Kozak CA, Audus KL. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci U S A 1993; 90:9355-58; PMID:8415706; http://dx.doi.org/10.1073/pnas.90.20.9355
   PubMed Web of Science ®Google Scholar
• Schnurch H, Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 1993; 119:957-68; PMID:8187650
   PubMed Web of Science ®Google Scholar
• Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161-69; PMID:8980223; http://dx.doi.org/10.1016/S0092-8674(00)81812-7
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich J, Papadopoulos N, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60; PMID:9204896; http://dx.doi.org/10.1126/science.277.5322.55
   PubMed Web of Science ®Google Scholar
• Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009; 29:2011-22; PMID:19223473; http://dx.doi.org/10.1128/MCB.01472-08
   PubMed Web of Science ®Google Scholar
• Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013; 73:108-118; PMID:23149917; http://dx.doi.org/10.1158/0008-5472.CAN-12-2064
   PubMed Web of Science ®Google Scholar
• Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-39; PMID:16462802; http://dx.doi.org/10.1038/nm1351
   PubMed Web of Science ®Google Scholar
• Scholz A, Plate KH, Reiss Y. Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Ann N Y Acad Sci 2015; 1347:45-51; PMID:25773744; http://dx.doi.org/10.1111/nyas.12726
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Sugaya M, Suga H, Miyagaki T, Ohmatsu H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S. Serum levels of angiopoietin-2, but not angiopoietin-1, are elevated in patients with erythrodermic cutaneous T-cell lymphoma. Acta Derm Venereol 2014; 94:9-13; PMID:23817541; http://dx.doi.org/10.2340/00015555-1633
   PubMed Web of Science ®Google Scholar
• Park JH, Choi H, Kim YB, Kim YS, Sheen SS, Choi JH, Lee HL, Lee KS, Chung WY, Lee S, et al. Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer. Lung Cancer 2009; 66:359-64; PMID:19339077; http://dx.doi.org/10.1016/j.lungcan.2009.03.002
   PubMed Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507-16; PMID:15542434; http://dx.doi.org/10.1016/j.ccr.2004.09.030
   PubMed Web of Science ®Google Scholar
• Coutelle O, Schiffmann LM, Liwschitz M, Brunold M, Goede V, Hallek M, Kashkar H, Hacker UT. Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours. Br J Cancer 2015; 112:495-503; PMID:25562438; http://dx.doi.org/10.1038/bjc.2014.629
   PubMed Web of Science ®Google Scholar
• Liontos M, Lykka M, Dimopoulos MA, Bamias A. Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. Onco Targets Ther 2014; 7:1837-45; PMID:25336975
   PubMed Web of Science ®Google Scholar
• Robson EJ, Ghatage P. AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 2011; 20:297-304; PMID:21210755; http://dx.doi.org/10.1517/13543784.2011.549125
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamamoto H, Ngan CY, Ohtsuka M, Kitani K, Uemura M, Nishimura J, Takemasa I, Mizushima T, Sekimoto M, S et al. Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo. Int J Oncol 2013; 43:1447-55; PMID:23982687
   PubMed Web of Science ®Google Scholar
• Brown LF, Dezube BJ, Tognazzi K, Dvorak HF, Yancopoulos GD. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 2000; 156:2179-83; PMID:10854238; http://dx.doi.org/10.1016/S0002-9440(10)65088-2
   PubMed Web of Science ®Google Scholar
• Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, Gratrix F, Takeuchi Y, Boshoff C. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res 2007; 67:4042-51; PMID:17483315; http://dx.doi.org/10.1158/0008-5472.CAN-06-3321
   PubMed Web of Science ®Google Scholar
• Ye FC, Blackbourn DJ, Mengel M, Xie JP, Qian LW, Greene W, Yeh IT, Graham D, Gao SJ. Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 2007; 81:3980-91; PMID:17287278; http://dx.doi.org/10.1128/JVI.02089-06
   PubMed Web of Science ®Google Scholar
• Ye FC, Zhou FC, Nithianantham S, Chandran B, Yu XL, Weinberg A, Gao SJ. Kaposi's sarcoma-associated herpesvirus induces rapid release of angiopoietin-2 from endothelial cells. J Virol 2013; 87:6326-35; PMID:23536671; http://dx.doi.org/10.1128/JVI.03303-12
   PubMed Web of Science ®Google Scholar
• An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, McCrae KR, Fakhari FD, Dittmer DP, Renne R. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 2006; 80:4833-46; PMID:16641275; http://dx.doi.org/10.1128/JVI.80.10.4833-4846.2006
   PubMed Web of Science ®Google Scholar
• Brulois KF, Chang H, Lee AS, Ensser A, Wong LY, Toth Z, Lee SH, Lee HR, Myoung J, Ganem D, et al. Construction and manipulation of a new Kaposi's sarcoma-associated herpesvirus Bacterial artificial chromosome clone. J Virol 2012; 86:9708-20; PMID:22740391; http://dx.doi.org/10.1128/JVI.01019-12
   PubMed Web of Science ®Google Scholar
• Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, Kriz W, Thurston G, Augustin HG. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150-56; PMID:14976056; http://dx.doi.org/10.1182/blood-2003-10-3685
   PubMed Web of Science ®Google Scholar
• Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 2001; 61:2145-53; PMID:11280779
   PubMed Web of Science ®Google Scholar
• Biel NM, Siemann DW. Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett 2014; S0304-3835(14):00576-X.
   Google Scholar
• Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 2013; 73:1649-57; PMID:23467610; http://dx.doi.org/10.1158/0008-5472.CAN-12-4697
   PubMed Web of Science ®Google Scholar
• Boshoff C, Chang Y. Kaposi's sarcoma-associated herpesvirus: a new DNA tumor virus. Annu Rev Med 2001; 52:453-70; PMID:11160789; http://dx.doi.org/10.1146/annurev.med.52.1.453
   PubMed Web of Science ®Google Scholar
• Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu JH, Bartol A, Kienast Y, Vettel C, Loos EK, et al. Angiopoietin-2 differentially regulates angiogenesis through Tie-2 and integrin signaling. J Clin Invest 2012; 122:1991-2005; PMID:22585576; http://dx.doi.org/10.1172/JCI58832
   PubMed Web of Science ®Google Scholar
• Hakanpaa L, Sipila T, Leppanen VM, Gautam P, Nurmi H, Jacquemet G, Eklund L, Ivaska J, Alitalo K, Saharinen P. Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nat Commun 2015; 6:5962; PMID:25635707; http://dx.doi.org/10.1038/ncomms6962
   PubMed Web of Science ®Google Scholar
• Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007; 178:7405-11; PMID:17513791; http://dx.doi.org/10.4049/jimmunol.178.11.7405
   PubMed Web of Science ®Google Scholar
• Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109:5276-85; PMID:17327411; http://dx.doi.org/10.1182/blood-2006-10-053504
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A, Plate KH, Reiss Y, Murdoch C, De Palma M, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011; 186:4183-90; PMID:21368233; http://dx.doi.org/10.4049/jimmunol.1002802
   PubMed Web of Science ®Google Scholar
• Scholz A, Lang V, Henschler R, Czabanka M, Vajkoczy P, Chavakis E, Drynski J, Harter PN, Mittelbronn M, Dumont DJ, et al. Angiopoietin-2 promotes myeloid cell infiltration in a β(2)-integrin-dependent manner. Blood 2011; 118:5050-59; PMID:21868579; http://dx.doi.org/10.1182/blood-2011-03-343293
   PubMed Web of Science ®Google Scholar
• Corliss BA, Azimi MS, Munson J, Peirce SM, Murfee WL. Macrophages: An Inflammatory Link between Angiogenesis and Lymphangiogenesis. Microcirculation 2015; 23:95-121; http://dx.doi.org/10.1111/micc.12259
   Web of Science ®Google Scholar
• Komohara Y, Niino D, Ohnishi K, Ohshima K, Takeya M. Role of tumor-associated macrophages in hematological malignancies. Pathol Int 2015; 65:170-76; PMID:25707506; http://dx.doi.org/10.1111/pin.12259
   PubMed Web of Science ®Google Scholar
• Atkins MB, Gravis G, Drosik K, Demkow T, Tomczak P, Wong SS, Michaelson MD, Choueiri TK, Wu B, Navale L, et al. Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. J Clin Oncol 2015; 33:3431-38; PMID:26304872; http://dx.doi.org/10.1200/JCO.2014.60.6012
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Stein CA, Pal SK. Targeting angiopoietin-2 signaling in cancer therapy. Expert Opin Investig Drugs 2013; 22:813-25; PMID:23621441; http://dx.doi.org/10.1517/13543784.2013.793306
   PubMed Web of Science ®Google Scholar
• Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2011; 9:CD007930.
   Google Scholar
• Neal J, Wakelee H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther 2010; 12:487-95; PMID:20677100
   PubMed Web of Science ®Google Scholar
• Ye FC, Lattif AA, Xie JP, Weinberg A, Gao SJ. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi's sarcoma tumor cells. Cell Cycle 2012; 11:1393-99; PMID:22421142; http://dx.doi.org/10.4161/cc.19756
   PubMed Web of Science ®Google Scholar
• Ensley JF, Maciorowski Z, Pietraszkiewicz H, Klemic G, KuKuruga M, Sapareto S, Corbett T, Crissman J. Solid tumor preparation for flow cytometry using a standard murine model. Cytometry 1987; 8:479-87; PMID:2444398; http://dx.doi.org/10.1002/cyto.990080508
   PubMedGoogle Scholar